To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.
Summary
What This Bill Does
The bill creates expansion of registry and results data bank to include costs of drug clinical trials Section 402(j) of the Public Health Service Act (42 U.S.C and requires disclosure of research and development expenditures by drug manufacturers Section 13 of the Securities Exchange Act of 1934 (15 U.S.C. It relies on definition changes, reporting requirements, appropriations, and grants. The main policy areas are Healthcare Consumers, Environment, Finance, and Healthcare.
Who Benefits and How
Researchers and scientific institutions affected by the bill could face lower compliance burdens, Patients and health care consumers affected by the bill could face lower compliance burdens, and Financial services firms and customers affected by the bill could face lower compliance burdens.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Researchers and scientific institutions affected by the bill would take on compliance duties, and Patients and health care consumers affected by the bill would take on compliance duties.
Key Provisions
- Creates expansion of registry and results data bank to include costs of drug clinical trials Section 402(j) of the Public Health Service Act (42 U.S.C.
- Requires disclosure of research and development expenditures by drug manufacturers Section 13 of the Securities Exchange Act of 1934 (15 U.S.C.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates expansion of registry and results data bank to include costs of drug clinical trials Section 402(j) of the Public Health Service Act (42 U.S.C and requires disclosure of research and development expenditures by drug manufacturers Section 13 of the Securities Exchange Act of 1934 (15 U.S.C.
Key Policy Areas
Healthcare Consumers, Environment, Finance, Healthcare
Primary Purpose
The bill creates expansion of registry and results data bank to include costs of drug clinical trials Section 402(j) of the Public Health Service Act (42 U.S.C and requires disclosure of research and development expenditures by drug manufacturers Section 13 of the Securities Exchange Act of 1934 (15 U.S.C.
Policy Domains
Whole bill
Identified Gains
- Researchers and scientific institutions affected by the bill
- Patients and health care consumers affected by the bill
- Financial services firms and customers affected by the bill
- Environmental and public health interests affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Researchers and scientific institutions affected by the bill
- Patients and health care consumers affected by the bill
- Financial services firms and customers affected by the bill
- Environmental and public health interests affected by the bill
Sponsors
Legislative Progress
IntroducedMs. Stabenow (for herself, Ms. Smith, and Mr. Welch) introduced …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology